Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Immunohistochemical study of receptor activator of nuclear factor kappa-B ligand (RANK-L) in human osteolytic bone tumors.

Good CR, O'Keefe RJ, Puzas JE, Schwarz EM, Rosier RN.

J Surg Oncol. 2002 Mar;79(3):174-9.

PMID:
11870668
2.

RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.

Sordillo EM, Pearse RN.

Cancer. 2003 Feb 1;97(3 Suppl):802-12. Review.

3.
4.
5.

Identification of new targets for therapy of osteolytic bone disease in multiple myeloma.

Hjertner Ø, Standal T, Børset M, Sundan A, Waage A.

Curr Drug Targets. 2005 Sep;6(6):701-11. Review.

PMID:
16178802
6.

RANKL signaling in bone physiology and cancer.

Dougall WC.

Curr Opin Support Palliat Care. 2007 Dec;1(4):317-22. doi: 10.1097/SPC.0b013e3282f335be. Review.

PMID:
18685382
7.

The RANK/RANKL/OPG triad in cancer-induced bone diseases.

Dougall WC, Chaisson M.

Cancer Metastasis Rev. 2006 Dec;25(4):541-9. Review.

PMID:
17180711
8.

RANK ligand and osteoprotegerin in myeloma bone disease.

Sezer O, Heider U, Zavrski I, Kühne CA, Hofbauer LC.

Blood. 2003 Mar 15;101(6):2094-8. Review.

9.

Update on the pathogenesis of osteolysis in multiple myeloma patients.

Giuliani N, Colla S, Rizzoli V.

Acta Biomed. 2004 Dec;75(3):143-52. Review.

PMID:
15796087
10.

Key roles of the OPG-RANK-RANKL system in bone oncology.

Baud'huin M, Duplomb L, Ruiz Velasco C, Fortun Y, Heymann D, Padrines M.

Expert Rev Anticancer Ther. 2007 Feb;7(2):221-32. Review.

PMID:
17288531
11.

[Bone remodeling and mineral homeostasis].

Nakamura M, Udagawa N, Nakamura H.

Clin Calcium. 2006 Jan;16(1):46-53. Review. Japanese.

PMID:
16397350
13.

Bone lesions in multiple myeloma--the OPG/RANK-ligand system.

Goranov SE, Goranova-Marinova VS.

Folia Med (Plovdiv). 2004;46(3):5-11. Review.

PMID:
15819451
14.

Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.

Blair JM, Zhou H, Seibel MJ, Dunstan CR.

Nat Clin Pract Oncol. 2006 Jan;3(1):41-9. Review.

PMID:
16407878
15.

[Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].

Mochizuki S, Kiyokawa A, Nagayama Y.

Clin Calcium. 2005 Jan;15(1):35-42. Review. Japanese.

PMID:
15632471
16.

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.

Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D.

Cytokine Growth Factor Rev. 2004 Dec;15(6):457-75. Review.

PMID:
15561602
17.

[Histopathological observations on osteolytic bone metastasis].

Li M, Amizuka N.

Clin Calcium. 2006 Apr;16(4):591- 97. Review. Japanese.

PMID:
16582509
18.

[Role of osteoclast differentiation factor, the new member of the TNF ligand family, in osteoclast differentiation and function].

Takahashi N, Udagawa N, Suda T.

Seikagaku. 1999 Apr;71(4):241-53. Review. Japanese. No abstract available.

PMID:
10358436
19.

Mechanisms of bone metastasis.

Roodman GD.

N Engl J Med. 2004 Apr 15;350(16):1655-64. Review. No abstract available.

PMID:
15084698
20.

Bone metastasis: histological changes and pathophysiological mechanisms in osteolytic or osteosclerotic localizations. A review.

Chappard D, Bouvard B, Baslé MF, Legrand E, Audran M.

Morphologie. 2011 Jun;95(309):65-75. doi: 10.1016/j.morpho.2011.02.004. Review.

PMID:
21620753
Items per page

Supplemental Content

Support Center